QuintilesIMS Named Best Full-service Provider CRO in 2016 Scrip Awards
Award acknowledges the critical role CROs play in drug development
“We are delighted to receive this distinction once again this year,” said Cynthia Verst, president, Clinical Operations, QuintilesIMS. “The Scrip Awards are among the most sought after in the biopharmaceutical industry, and we are extremely pleased to have been honored with this award. Being selected for this recognition reinforces the impact we have in the biopharmaceutical industry as well as the important role we serve in creating solutions that help our clients drive healthcare forward.”
The “Best Full-service Provider CRO” award acknowledges the critical role that CROs play in drug development and is judged on the full range of services provided by CRO companies. These criteria and services include the quality of relationships they have built with their clients as well as innovative approaches they leverage for data management and patient recruitment strategies.
QuintilesIMS brings the ability to access vast amounts of complex healthcare data paired with sophisticated analytics and world-class science and therapeutic specialization expertise. Working alongside its clients, QuintilesIMS is focused on transforming clinical development by connecting healthcare data, new technologies, advanced methodologies and scientific expertise - capabilities that helped distinguish the company from a highly competitive field once again this year.
An independent panel of 15 life sciences experts judges the nominations, making the Scrip Awards an important recognition of excellence in the biopharmaceutical industry.
“Our judges felt QuintilesIMS was a worthy winner of this year’s Best Contract Research Organization trophy, one of the most competitive categories at the Scrip Awards,” said Mike Ward, global director of content for Informa Pharma Insights portfolio. “Despite plenty of competition, QuintilesIMS continues to set the pace.”
The 12th annual awards ceremony was held in London, UK with biopharmaceutical industry leaders from around the world in attendance.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.
As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device, and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.quintilesims.com.
Click here to subscribe to Mobile Alerts for QuintilesIMS.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161201005687/en/
Website: http://www.QuintilesIMS.com
Contact
QuintilesIMS
Media Relations:
Phil Bridges
+ 1-919-998-1653
Mobile: +1-919-457-6347
phil.bridges@quintilesims.com
Tor Constantino
+ 1-484-567-6732
Mobile: +1-240-672-2953
tor.constantino@quintilesims.com
Investor Relations:
Thomas Kinsley
+1-203-448-4691
thomas.kinsley@quintilesims.com
Andrew Markwick
+1-973-257-7144
andrew.markwick@quintilesims.com
This news is a press release provided by QuintilesIMS. Korea Newswire follows these editorial guidelines.
-
2016년 12월 2일 18:15
-
2016년 10월 25일 13:30